Follow
Shai Mulinari
Shai Mulinari
Sociology, Lund University.
Verified email at soc.lu.se - Homepage
Title
Cited by
Cited by
Year
Monoamine theories of depression: historical impact on biomedical research
S Mulinari
Journal of the History of the Neurosciences 21 (4), 366-392, 2012
1742012
Chronic obstructive pulmonary disease in Sweden: an intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy
SA Fisk, S Mulinari, M Wemrell, G Leckie, RP Vicente, J Merlo
SSM-population health 4, 334-346, 2018
1192018
The tyranny of the averages and the indiscriminate use of risk factors in public health: the case of coronary heart disease
J Merlo, S Mulinari, M Wemrell, SV Subramanian, B Hedblad
SSM-population health 3, 684-698, 2017
942017
Sunshine policies and murky shadows in Europe: disclosure of pharmaceutical industry payments to health professionals in nine European countries
A Fabbri, A Santos, S Mezinska, S Mulinari, B Mintzes
International Journal of Health Policy and Management 7 (6), 504, 2018
872018
Intersectionality and risk for ischemic heart disease in Sweden: Categorical and anti-categorical approaches
M Wemrell, S Mulinari, J Merlo
Social Science & Medicine 177, 213-222, 2017
862017
Contemporary epidemiology: a review of critical discussions within the discipline and a call for further dialogue with social theory
M Wemrell, J Merlo, S Mulinari, AC Hornborg
Sociology Compass 10 (2), 153-171, 2016
852016
Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004–2012: a quantitative and qualitative study of pharmaceutical industry self …
AV Zetterqvist, J Merlo, S Mulinari
PLoS medicine 12 (2), e1001785, 2015
692015
Exposing drug industry funding of UK patient organisations
P Ozieranski, E Rickard, S Mulinari
Bmj 365, 2019
642019
DRhoGEF2 and Diaphanous Regulate Contractile Force during Segmental Groove Morphogenesis in the Drosophila Embryo
S Mulinari, MP Barmchi, U Häcker
Molecular biology of the cell 19 (5), 1883-1892, 2008
592008
Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK …
S Mulinari, P Ozieranski
BMJ open 8 (10), e023094, 2018
492018
Pharmaceutical industry off-label promotion and self-regulation: a document analysis of off-label promotion rulings by the United Kingdom prescription medicines code of …
A Vilhelmsson, C Davis, S Mulinari
PLoS medicine 13 (1), e1001945, 2016
452016
Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation
AV Zetterqvist, S Mulinari
PLOS one 8 (5), e62609, 2013
432013
Analysis of pharmaceutical industry payments to UK health care organizations in 2015
P Ozieranski, M Csanadi, E Rickard, J Tchilingirian, S Mulinari
JAMA Network Open 2 (6), e196253-e196253, 2019
422019
Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
S Mulinari, L Martinon, PA Jachiet, P Ozieranski
Health Policy 125 (7), 915-922, 2021
402021
An intersectional approach to multilevel analysis of individual heterogeneity (MAIH) and discriminatory accuracy
M Wemrell, S Mulinari, J Merlo
Soc Sci Med 178, 217-9, 2017
372017
Questioning the discriminatory accuracy of broad migrant categories in public health: self-rated health in Sweden
S Mulinari, A Bredström, J Merlo
The European journal of public health 25 (6), 911-917, 2015
372015
Expression and regulation of Spätzle-processing enzyme in Drosophila
S Mulinari, U Häcker, C Castillejo-López
FEBS letters 580 (22), 5406-5410, 2006
372006
Two-thirds of survey respondents in southern Sweden used complementary or alternative medicine in 2015
M Wemrell, J Merlo, S Mulinari, AC Hornborg
Complementary medicine research 24 (5), 302-309, 2017
352017
Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
S Mulinari, C Davis, P Ozieranski
Journal of White Collar and Corporate Crime 2 (2), 69-80, 2021
342021
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
S Mulinari, A Vilhelmsson, E Rickard, P Ozieranski
PLoS One 15 (6), e0235021, 2020
322020
The system can't perform the operation now. Try again later.
Articles 1–20